Literature DB >> 6332131

OKT4+ cytotoxic T cells can lyse targets via class I molecules and can be blocked by monoclonal antibody against T4 molecules.

G Strassman, F H Bach.   

Abstract

Human cytotoxic T lymphocytes (CTL) have been shown to recognize either class I or class II major histocompatibility (MHC) products. This recognition has been correlated with the expression of OKT antigens on the surface of the CTL. Thus, OKT4+ CTL have been shown to be reactive with class II products, whereas OKT8+ effectors recognize class I molecules. In this study, responder cells were separated according to their OKT4 or OKT8 cell surface phenotype on a fluorescence-activated cell sorter (FACS). The OKT4+ subsets were stimulated with an LCL mutant that did not express DR and MB/MT but did express SB and class I antigens. After 7 days in culture, the activated subsets were tested on a panel of class I matched or mismatched targets. The cytotoxicity observed could be correlated with the presence of matched class I antigens. In addition, monoclonal antibody (MCA) W6/32, directed at a monomorphic determinant on HLA-A and -B molecules, blocked lysis. Furthermore, six OKT4+ CTL clones were derived from the OKT4+ bulk cultures; three clones were found to be directed at class I molecules whereas the other three recognized class II determinants. The ability of these clones to lyse their relevant targets was blocked by OKT4 MCA, raising questions as to the role of the T4 molecule in antigen class-specific CTL recognition.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332131

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis.

Authors:  R M Hoffmann; G R Pape; U Spengler; E P Rieber; J Eisenburg; J Döhrmann; G Paumgartner; G Riethmüller
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

2.  Gut microbiota amplifies host-intrinsic conversion from the CD8 T cell lineage to CD4 T cells for induction of mucosal immune tolerance.

Authors:  Jen Bon Lui; Lander S McGinn; Zhibin Chen
Journal:  Gut Microbes       Date:  2016

3.  Functional characterization of infiltrating T lymphocytes in human hepatic allografts.

Authors:  J J Fung; A Zeevi; T E Starzl; J Demetris; S Iwatsuki; R J Duquesnoy
Journal:  Hum Immunol       Date:  1986-06       Impact factor: 2.850

4.  Effect of recombinant soluble CD4 on human peripheral blood lymphocyte responses in vitro.

Authors:  M A Liu; T Liu
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Lymph Node Stromal Cell-Intrinsic MHC Class II Expression Promotes MHC Class I-Restricted CD8 T Cell Lineage Conversion to Regulatory CD4 T Cells.

Authors:  Amanda M Honan; Emily N Vazquez; Zhibin Chen
Journal:  J Immunol       Date:  2021-08-18       Impact factor: 5.426

6.  Trojan horse lymphocytes: a vesicular stomatitis virus-specific T-cell clone lyses target cells by carrying virus.

Authors:  R C Hom; G Soman; R Finberg
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

7.  Recognition of Epstein-Barr virus (EBV)-infected cells by T cell colonies from a human chimera: restriction by allogeneic determinants.

Authors:  H Plotnicky; J L Touraine
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

8.  Major histocompatibility complex class I-restricted alloreactive CD4+ T cells.

Authors:  Louise H Boyle; Jane C Goodall; J S Hill Gaston
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

9.  Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells.

Authors:  D S Hoon; Y Hayashi; T Morisaki; L J Foshag; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

10.  T cell requirements for the rejection of renal allografts bearing an isolated class I MHC disparity.

Authors:  J A Gracie; E M Bolton; C Porteous; J A Bradley
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.